Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Gutzmer, Ralf; Stroyakovskiy, Daniil; Gogas, Helen; Robert, Caroline; Lewis, Karl; Protsenko, Svetlana; Pereira, Rodrigo P.; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Manikhas, Georgy Moiseevich; Yan, Yibing; Huang, Kuan-Chieh; Uyei, Anne; McNally, Virginia; McArthur, Grant A.; Ascierto, Paolo A.

dc.contributor.author	Eigentler, Thomas
dc.date.accessioned	2021-01-14T15:01:37Z
dc.date.available	2021-01-14T15:01:37Z
dc.date.issued	2020
dc.identifier.issn	1474-547X
dc.identifier.uri	http://hdl.handle.net/10900/111563
dc.language.iso	en	de_DE
dc.publisher	Elsevier Science Inc	de_DE
dc.relation.uri	https://doi.org/10.1016/S0140-6736(20)30934-X	de_DE
dc.subject.ddc	610	de_DE
dc.title	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial	de_DE
dc.type	Article	de_DE
utue.quellen.id	20200929220116_00863
utue.publikation.seiten	1835-1844	de_DE
utue.personen.roh	Gutzmer, Ralf
utue.personen.roh	Stroyakovskiy, Daniil
utue.personen.roh	Gogas, Helen
utue.personen.roh	Robert, Caroline
utue.personen.roh	Lewis, Karl
utue.personen.roh	Protsenko, Svetlana
utue.personen.roh	Pereira, Rodrigo P.
utue.personen.roh	Eigentler, Thomas
utue.personen.roh	Rutkowski, Piotr
utue.personen.roh	Demidov, Lev
utue.personen.roh	Manikhas, Georgy Moiseevich
utue.personen.roh	Yan, Yibing
utue.personen.roh	Huang, Kuan-Chieh
utue.personen.roh	Uyei, Anne
utue.personen.roh	McNally, Virginia
utue.personen.roh	McArthur, Grant A.
utue.personen.roh	Ascierto, Paolo A.
dcterms.isPartOf.ZSTitelID	Lancet	de_DE
dcterms.isPartOf.ZS-Issue	10240	de_DE
dcterms.isPartOf.ZS-Volume	395	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE